88 results about "Immune inhibition" patented technology

Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.

The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.

The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a cytotoxic T-lymphocyte inducing composition and at least one agent which is capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors, separately or in combination.

The present invention discloses methods of using of compounds for the enhancement of the innate immune system of a patient. In particular, the active compounds of the present invention include at least one calcineurin inhibitor, mTOR inhibitor or non-immunosuppresive derivative, or a derivative, isomer, or pharmaceutically acceptable salt thereof; and optionally, at least one calciferol or LMW inhibitor, or a derivative, isomer, or pharmaceutically acceptable salt thereof. Pharmaceutical formulations comprising same are also disclosed.

The present invention relates to a production process of the rosmarinic acid by absorbing the resin with a large hole, separation and purification of the plant containing the rosmarinic acid. The key technical points are: the plant containing the rosmarinic acid is used as the raw material; the extraction liquid is absorbed with a large hole, purified, eluted and vacuum dried to get the refined rosmarinic acid product. The purity of the product can reach above 90 percent. The present invention successfully uses the macroporous absorption technology of the resin in the one-step refinement, separation and purification of the rosmarinic acid. The rosmarinic acid produced in the present invention has the good antioxidant properties; the pharmacological effects of the rosmarinic acid are relatively strong; the effects of the immune inhibition, microbial inhibition, anti-inflammation, anti-thrombotic and anti-platelet aggregation, anti-allergic and other performances are significant. The present invention provides the possibility for the refining production of the large-scale industrialization of the rosmarinic acid product with the high biological activity, and lays the foundation for the further development and the wide application of the active product.

A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and predicting a treatment outcome. Methods of detecting defects in monocyte or T lymphocyte function, including the steps of administering an effective amount of an NCM or T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and detecting at least one defect in monocyte or T lymphocyte function. A mechanism for indicating a functioning efferent or afferent limb of an immune system, including a diagnostic skin test including an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3.

The present invention pertains to engineered immortalized T-cell lines, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immortalized T-cell lines of the invention are characterized in that the expression of endogenous T-cell receptors (TCRs) and beta 2-microglobulin (B2M) is inhibited, e.g., by using an endonuclease able to selectively inactivate the TCR and B2M genes in order to render the immortalized T-cells non-alloreactive. In addition, expression of immunosuppressive polypeptide can be performed on those engineered immortalized T-cells in order to prolong the survival of these T-cells in host organisms. Such engineered immortalized T-cells are particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the host's immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immortalized T-cells for treating cancer, infections and auto-immune diseases.

The present invention relates generally to the use of compounds, compositions, combinations, kits, and methods for the effective endocytic presentation of immunosuppressive factors for the down regulation of diabetogenic T cells for the treatment of type I diabetes.

The invention relates to a Chinese medicinal decoction for treating leucocytopenia caused by chemotherapy for cancer, and also to the process for preparation, wherein the constituents include (by weigh ratio) root of American ginseng 20g, hairy deerhorn 30g, ganoderma lucidum 20g, astragalus root 30g, fruit of barbary wolf berry 20g, Chinese caterpillar fungus 20g, dry human placenta 20g, aniseed 10g, prepared aconite root 20g, notoginseng 10g, euphoria longan steud 20g, white atractylodes rhizome 10g, Ficus carica 20g, dried rehmannia root 20g, psoralea fruit 10g, aloe 10g, turtle shell 10g, ophiopogon root 10g, ligustrum japonicum 20g, Siberian solomonseal rhizome 10g, broomrape 10g, mongloian snakegourd 10g, root of herbaceous peony 10g, coix seed 10g, cornus officinalis 10g, rhubarb horsetails 5g, cape jasmine 5g, schisandra fruit 10g, licorice root 10g, lily bulb 5g.

The invention relates to conjugates of saturated aliphatic chain alcohol, dexamethasone, and Glu-Asp-Gly, preparation, a nano structure, and applications thereof. The invention discloses 6 saturated aliphatic chain alcohol modified dexamethasone-Glu-Asp-Gly conjugates represented by the formula 10 a-f, wherein in the formula the n represents 7, 9, 11, 13, 15, or 17. The invention also discloses a preparation method, a nano structure, immunity inhibition activity, inflammation inhibition activity, and pain relieving activity of the conjugates. The invention also finds that the conjugates do not have any side effect leading to osteoporosis. The researches on the inhibition effect of the conjugates on splenic lymphocyte mitogen proliferation reactions and the survival time after mouse retroauricular cardiac muscle transplant show that the conjugates have an excellent immunity inhibition effect. The researches on the effect of the conjugates on the swelling degree of mouse ears which are inflamed due to xylene show that the conjugates have an excellent anti-inflammation effect. The researches on the effect of the conjugates on mouse heat radiation tail flick time show that the conjugates have an excellent pain-relieving effect. The researches on the effect of the conjugates on the mouse thigh bones show that the conjugates cannot cause osteoporosis. So the conjugates have a wide application prospect in the preparation of immunity inhibition drugs.

A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic, angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a methotrexate based medicament, wherein the methotrexate based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the methotrexate based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.

The invention discloses an application of polygonatum polysaccharide in the preparation of drugs for assisting the inhibition of colon cancer. The polygonatum polysaccharide is preferably prepared through the following steps: adopting polygonatum sibiricum as the raw material, extracting the polygonatum sibiricum with boiling water, removing the proteins, carrying out dialysis, and finally carrying out an ethanol treatment so as to obtain the polygonatum polysaccharide. The polygonatum polysaccharide can modulate the tumor micro-environment by inhibiting the tumor from generating new vessels, carrying out immunity inhibition, carrying out anti-oxidation, inhibiting the growth of colon cancer fibroblast, and the like. Thus the polygonatum polysaccharide has a very good auxiliary effect on inhibiting the colon tumor.

Disclosed is a transfer factor solution for animals, wherein its preparing process consists of washing freeze chicken spleens and chopping, charging distilled water and comminuting cells to homogenate, freezing eight times at minus 30 deg C, centrifuging the homogenated liquid, separating deposition and filtering supernatant fluid with microporous filtering film, carrying out hyperfiltration with ultrafiltration membrane to obtain stock solution, removing viruses, charging niacinamide as stabilizer, filtering and degerming through microporous filtering film, charging glycerine and split charging directly.

Through the experiments and researches on calycosin, it has been found for the first time that calycosin can prominently inhibit the T lymphocyte proliferation induced by concanavalin A (Con A), has an immunity inhibiting effect, and is advantageously used to prepare immunity inhibitors.

The invention discloses a feed additive for reducing cow body cells and treating recessive mastitis and a preparation method of the feed additive. The feed additive is prepared from the following raw materials in parts by weight: 10-15 parts of antibacterial peptide, 5-10 parts of geobacillus sp, 10-15 parts of yeast, 15-20 parts of cottonrose hibiscus leaf, 20-30 parts of andrographis paniculata, 10-20 parts of thesium chinense, 5-10 parts of cowherb seed, 15-20 parts of mongolian dandelion herb, 10-20 parts of epimedium, 20-30 parts of astragalus membranaceus, 5-10 parts of lindera aggregata leaf, 1-5 parts of sea buckthorn seed powder, 1-5 parts of corn pollen, 0.2-0.3 part of organic chelated zinc, 0.3-1 part of organic chromium and 8-15 parts of coated threonine. The additive can quickly reduce the body cell number, quickly cure the recessive mastitis, enable a cow to quickly restore to be the healthy production state, avoid generation of clinical mastitis, comprehensively improve the immunologic function of the body of the cow in the lactation period, effectively prevent generation of various diseases, highly improve the anti-stress capability of the cow in the perinatal period, effectively prevent generation of antenatal and puerperal diseases, highly improve the vaccine protection rate, strengthen the immune antibody level, and avoid immune clearance, immune inhibition and vaccine stress.

The invention discloses an application of triacetyl andrographolide to prepare antiphlogistic, immune inhibition and antineoplastic drug, which can be drug composition of medically acceptable carrier as active component.

The invention relates to a traditional Chinese medicine composition and an ointment for treating rheumatism, and a preparation method thereof. The traditional Chinese medicine composition can effectively solve the problems of poor effect and toxic side effect of the drugs for treating rheumatism. A technical scheme is as below: the composition comprises the following raw materials by weight: 13-17g of Chinese angelica, 9-11g of Ligusticum wallichii, 9-11g of pseudo-ginseng, 13-17g of safflower, 9-11g of teasel root, 9-11g of radix angelicae tuhuo, 9-11g of notopterygium root, 13-17g of lycopodium clavatum, 13-17g of dahurian angelica root, 13-17g of radix sileris, 9-11g of Radix cyathulae, 9-11g of frankincense, 9-11g of myrrh and 4-6g of preparemonkshd moter root. The traditional Chinese medicine composition ointment uses pure natural traditional Chinese medicines as raw materials, the medicines organically coordinate, mutually support to reach reasonable compatibility. The composition has the advantages of abundant raw materials, simple method, good anti-inflammation, analgesia and immune inhibitory effects, good curative effect and low cost, and is a great innovation in the medicaments for treating rheumatism.

Compositions, methods, and uses of recombinant B7-H4 protein or binding motifs to B7-H4 protein that can reduce the immune suppression effect of B7-H4 in relation to T cell activation, proliferation, and conversion. Preferably, the recombinant B7-H4 protein has a plurality of mutations in N-glycosylation residue to reduce its inhibitory effect to T cell activation and proliferation. The recombinant protein having binding motifs to B7-H4 protein preferably includes a binding motif to IgC domain and another binding motif to IgV domain such that the immune-suppressive effects by two Ig-like domains are concurrently reduced.

A nucleic acid construct and an immune cell, which harbor nucleic acids encoding a CAR and nucleic acids encoding at least one anti-inflammatory or immunosuppressant protein and methods of using the same in treatment or amelioration of inflammation or immune-mediated autoimmunity are described.

The present invention provides an active immune regulation particle. The active immune regulation particle comprises a microcarrier, the microcarrier is loaded with at least SYNZIP1 polypeptide, SYNZIP2 polypeptide, nucleic acid molecule CpG, a T cell promoter, an antibody Fc segment and an antigen, an amino acid sequence of the SYNZIP1 polypeptide is shown in SEQ ID NO:1 and an amino acid sequence of the SYNZIP2 polypeptide is shown in SEQ ID NO:2. The active immune regulation particle can overcome immune suppression environment of tumor microenvironment, breaks immune tolerance, improves immune response of the entire immune system to tumor antigens, quickly and efficiently activate immune responses of tumor-specific B cells and T cells to kill tumors, and can also promote proliferation of the immune cells through stimulation by cytokines. Through administration by subcutaneous injection, the active immune regulation particle can be passively targeted into tumor tissues through capillaries and quickly endocytosed by the immune cells and tumor cells.